contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


active-biotechs-nomination-committee-appointed-5

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Active Biotech är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för cancer och autoimmuna sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Projektportföljen omfattar både små, oralt aktiva immunmodulerande molekyler samt antikroppsbaserad immunterapi. Bolaget är verksamt globalt. Active Biotech grundades 1998 och har sitt huvudkontor i Lund.

Active Biotech

In accordance with a decision made by the Annual General Meeting held on May 28, 2025, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes...

<div class="mfn-preamble"><p><strong>In accordance with a decision made by the Annual General Meeting held on May 28, 2025, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per end of September 2025, and the Chairman of the Board.</strong></p></div><div class="mfn-body"><p>If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.<br>Based on the above, the Nomination Committee is composed with participants representing the largest shareholders in Active Biotech as of September 30, 2025, and consists of:</p><p>Michael Shalmi, chairman<br>Mats Arnhög, MGA Holding<br>Peter Thelin, Sjuenda Holding<br>Petter Wingstrand, T-bolaget</p><p>For the 2026 Annual General Meeting, the Nomination Committee shall prepare and submit proposals regarding the Chairman of the AGM, the number of Board members, a Chairman and Board members elected by the AGM, the fees and other renumerations to Board members and Board committee´s, number of auditors, the auditor, fees to auditors and election of a Nomination Committee.</p></div><div class="mfn-footer mfn-contacts mfn-39926fa7db58"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Helén Tuvesson,&nbsp;<em>CEO</em>, +46 46 19 21 56, <a rel="noopener" href="https://www.globenewswire.com/Tracker?data=iFG1kvVIp5pKUTaCk0JiGzw9dl5sOO_9c1qJkW85IwkJ2q3yfKNYaxNkYx6dheJqlz7uzyshFUzqp1r58eX0EwmkE0v707I8o0lPBbqYY8UvgU199yEyZAn5dlfWfZO4">helen.tuvesson@activebiotech.com</a><br>Hans Kolam,&nbsp;<em>CFO</em>, +46 46 19 20 44,&nbsp;<a rel="noopener" href="https://www.globenewswire.com/Tracker?data=MR5_ToeY_jOzyHsukO6TttPqhmPsAbWR4pvo7PzeBD-PVZpENlc1ykgW0p6jbew_WmkeAMSZFzoNVxkl8nuvvBVhljBcYy9uABVnK5yHhZKIfjtRDFjP5TNN-jwbPdiWCxnYxOQCr1gRU1L5udq8QNYq3vgqNIrmfSf1E8uCbUY4kMhRORUZ0ZdijKi9A-QPkK6sbjrvP0yHKc0XZwaRAWbewx1p63FAFCock9Mybrm3wdpGuMxvELcnTuccE0HQF7XVdn4dPrJgjbA4Z0m7IkCDp1nqkpJod1DlYbgCbuA=">hans.kolam@activebiotech.com</a></p></div><div class="mfn-footer mfn-about mfn-4dca1f9d12f2"><p><strong class="mfn-heading-1">About Active Biotech</strong></p><hr><p><strong>Active Biotech AB (publ) (NASDAQ Stockholm: ACTI)</strong> is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies have been initiated. A clinical Phase Ib/IIa study in multiple myeloma has been concluded. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation has been performed to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit&nbsp;<a rel="noopener" href="http://www.activebiotech.com/en/">www.activebiotech.com</a>&nbsp;for more information.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/38361125-6bae-41f1-8880-d500d5ee76bd/active-biotechs-nomination-committee-appointed.pdf" class="mfn-generated mfn-primary">Active Biotech's nomination committee appointed</a></p></div>